NASDAQ : SRTS

Investor Relations

Company Overview

Sensus Healthcare, Inc. (NASDAQ: SRTS) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™, SRT-100+™ and SRT-100 Vision™.

Latest News

Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold

Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the "Fair Deal Agreement" recurring revenue program to provide...

Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats

First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...

Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia

Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological...

Stock Quote

Company

851 Broken Sound Parkway
Boca Raton, FL 33487
info@sensushealthcare.com

Phone 561.922.5808
Toll-free 800.324.9890
Fax 561.948.2071

Contact

Reception Phone Number: 561.922.5808
Reception Fax Number: 561.948.2071
Toll-free number: 800.324.9890
Email: info@sensushealthcare.com